吴思婧,刘宇扬

• 1:首都医科大学附属北京安贞医院12病房

摘要(Abstract)：

<正>抗血小板治疗自20世纪60年代在冠心病患者中应用以来,近30余年得到飞速发展,已成为冠心病治疗的基石。而在急性冠状动脉综合征(ACS)、药物洗脱支架(DES)置入术后患者中,双联抗血小板药物[阿司匹林联合血小板腺苷二磷酸(ADP)受体拮抗剂(如氯吡格雷)]治疗亦已成为常规治疗。然而业内对于接受双联抗血小板治疗最佳时长究竟为多少仍存在争议,近期《新英格兰杂志》总结美国心脏

关键词(KeyWords)： 抗血小板药物;消化道出血;质子泵抑制剂

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 吴思婧,刘宇扬

参考文献(References)：

• [1]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371:2155-2166.
• [2]Byrne RA,Schulz S,Mehilli J,et al.Rationale and design of a randomized,double-blind,placebo-controlled trial of 6 versus 12months clopidogrel therapy after implantation of a drug-eluting stent:The Intracoronary Stenting and Antithrombotic Regimen:Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting(ISAR-SAFE)study.Am Heart J,2009,157:620-624.e2.
• [3]Gilard M,Barragan P,Noryani AA,et al.Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:ITALIC,a randomized multicenter trial.J Am Coll Cardiol,2014.[Epub ahead of print].
• [4]Garratt KN,Weaver WD,Jenkins RG,et al.Prasugrel plus aspirin beyond 12 months is associated withimproved outcomes after Taxus Libertépaclitaxel-eluting coronary stent placement.Circulation,2015,131:62-73.
• [5]抗血小板药物消化道损伤的预防和治疗中国专家共识组.抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版).中华内科杂志,2013,52:264-270.
• [6]陈伟伟,高润霖,刘力生,等.中国心血管病报告2013概要.中国循环杂志,2014,29:487-491.
• [7]Yeomans ND,Lanas AI,Talley NJ,et al.Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protectivedoses of aspirin.Aliment Pharmacol Ther,2005,22:795-801.
• [8]McQ uaid KR,Laine L.Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel inrandomized controlled trials.Am J Med,2006,119:624-638.
• [9]Raju N,Sobieraj-Teague M,Hirsh J,et al.Effect of aspirin on mortality in the primary prevention of cardiovascular disease.Am J Med,2011,124:621-629.
• [10]Lanas A,García-Rodríguez LA,Arroyo MT,et al.Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors,traditional non-aspirin non-steroidal antiinflammatory drugs,aspirin and combinations.Gut,2006,55:1731-1738.
• [11]Bhatt DL,Fox KA,HackeW,et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.N Engl J Med,2006,354:1706-1717.
• [12]Nikolsky E,Stone GW,Kirtane AJ,et al.Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes:Incidence,Predictors,and Clinical ImplicationsA nalysis From the ACUITY(Acute Catheterizationand Urgent Intervention Triage Strategy)Trial.J Am Coll Cardiol,2009,54:1293-1302.
• [13]Saini SD,Fendrick AM,Scheiman JM.Cost-effectiveness analysis:cardiovascular benefits of proton pump inhibitor cotherapy inpatients using aspirin for secondary prevention.Aliment Pharmacol Ther,2011,34:243-251.
• [14]Ray WA,Murray KT,Griffin MR,et al.Outcomes with concurrent use of clopidogrel and proton-pump inhibitors:a cohort study.Ann Intern Med,2010,152:337-345.
• [15]Gilard M,Arnaud B,Cornily JC,et al.Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized,double-blind OCLA(Omeprazole CLopidogrel Aspirin)study.J Am Coll Cardiol,2008,51:256-260.
• [16]Gerson LB.Proton pump inhibitors and potential interactions with clopidogrel:an update.Curr Gastroenterol Rep,2013,15:329.
• [17]Bhatt DL,Cryer BL,Contant CF,et al.Clopidogrel with or without omeprazole in coronary artery disease.N Engl J Med,2010,363:1909-1917.
• [18]Simon T,Steg PG,Gilard M,et al.Clinical events as a function of proton pump inhibitor use,clopidogrel use,and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction:results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction(FAST-MI)registry.Circulation,2011,123:474-482.
• [19]Banerjee S,Weideman RA,Weideman MW,et al.Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.Am J Cardiol,2011,107:871-878.
• [20]Nakayama A,Morita H,Ando J,et al.Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.Heart Vessels,2013,28:292-300.
• [21]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial.Lancet,2010,376:1233-1243.
• [22]Kwok CS,Loke YK.Meta-analsis:theeffects of proton pump inhibitors on cardiovascular events and mortality in patientsreceiving clopidogrel.Aliment Pharmacol Ther,2010,31:810-823.
• [23]Siller-Matula JM,Jilma B,Schr?r K,et al.Effect of proton pump inhibitors onclinical outcome in patients treated with clopidogrel:a systematic review and meta-analysis.J Thromb Haemost,2010,8:2624-2641.
• [24]Focks JJ,Brouwer MA,van Oijen MG,et al.Concomitant use of clopidogrel and proton pump inhibitors:impact on platelet function and clinical outcome-a systematic review.Heart,2013,99:520-527.
• [25]Moukarbel GV,Bhatt DL.Antiplatelet therapy and proton pump inhibition:clinician update.Circulation,2012,125:375-380.
• [26]Goodman SG,Clare R,Pieper KS,et al.Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel andticagrelor:insights from the platelet inhibition and patient outcomes trial.Circulation,2012,125:978-986.
• [27]Storey RF,Angiolillo DJ,Patil SB,et al.Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes:the PLATO(PLATelet inhibition and patient Outcomes)PLATELET substudy.J Am Coll Cardiol,2010,56:1456-1462.
• [28]O'Donoghue ML,Braunwald E,Antman EM,et al.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomized trials.Lancet,2009,374:989-997.
• [29]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35:2541-2619.
• [30]Hsiao FY,Tsai YW,Huang WF,et al.A Comparison of Aspirin and Clopidogrel With or Without Proton Pump Inhibitors for the Secondary Prevention of Cardiovascular Events in Patients at High Risk for Gastrointestinal Bleeding.Clin Ther,2009,31:2038-2047.
• [31]中华内科杂志编委会,中华消化杂志编委会,中华消化内镜杂志编委会.急性非静脉曲张性上消化道出血诊治指南.中华内科杂志,2009,48:891-894.
• [32]Chan FK,Ching JY,Hung LC,et al.Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding.N Engl J Med,2005,352:238-244.
• [33]Abrahan NS,Hlatky MA,Antman EM,et al.ACCF/ACG/AHA2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines:a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.Circulation,2010,122:2619-2633.
• [34]Ishizaki T,Horai Y.Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.Aliment Pharmacol Ther,1999,13 Suppl 3:27-36.
• [35]Lin CF,Shen LJ,Wu FL,et al.Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.Br J Clin Pharmacol,2012,74:824-834.
• [36]Agewall S,Cattaneo M,Collet JP,et al.Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.Eur Heart J,2013,34:1708-1713,1713a-1713b.